Migraine Clinical Trial
Official title:
Physiological and Behavioral Effects of Osteopathic Manipulative Treatment on Patients With Chronic Headache: A Randomized Clinical Trial
Participants with chronic or recurrent headache, unrelated to any known pathology or disease, will be randomly assigned to one of four interventions: Osteopathic manipulation of the body other than the head, osteopathic manipulation of the head, osteopathic manipulation of the head and rest of the body, or light touch on the head only but no manipulation. Measurements of heart rate and blood pressure variability, peripheral blood flow, and behavioral changes, such as mood, pain duration, intensity and frequency will be assessed.
Sixty subjects will be recruited to participate in the study via word of mouth and mass
email notification of employees and students at Western University of Health Sciences in
Pomona, CA.
Patients will be randomly assigned to 1 of 4 groups for a specific Osteopathic Manipulative
Treatment (OMT): Compression of Fourth Ventricle (CV4) only, CV4 and subject appropriate
OMT, subject appropriate OMT only (no CV4), and sham (touch only). There will be 8 subjects
per OMT group, making it 24 subjects altogether assigned to one of the three OMT groups, and
24 sham subjects.
Power analysis for determination of sample sizes: The investigators have no data on
preliminary studies of the effect of OMT on chronic headaches, and there is only one study
of the immediate effect on tension type headache patients after CV4, so power analysis is a
rough estimate at this point for the one week headache symptom evaluation post OMT. From
preliminary studies in this lab, the investigators can expect for 'CV4 only' 80% of
participants to have significant still point objective response vs sham treatment which the
investigators expect will significantly effect about 10% of the participants. There needs to
be at least 16 subjects in each of two groups assessing this outcome measure, so 16
receiving CV4 and 16 sham to detect the 70% difference in still point measure. To detect
differences between any OMT and sham, since there are three groups receiving OMT of some
type, when the investigators consider how many in each of these three groups vs the sham
group, the investigators figured 8 per each OMT group, of which 2 are CV4 (thus 16 get CV4),
making it 24 subjects in the combined OMT groups. Therefore, the investigators need 24 sham
subjects to make it equal numbers for balanced analysis (OMT vs sham), and to detect
differences in the OMT interventions and sham interventions. Considering a possibility of
25%, or 12 subjects, not responding to the follow up survey at one week, the investigators
figured recruitment of 60 subjects would ensure the investigators would have enough to make
our calculations and be able to determine if there are significant differences between
groups.
The investigators have no preliminary studies on the effect of OMT or sham on mood in
patient with headaches, so this part of the study is an exploratory assessment and sample
size calculations will be able to be performed with the data gathered from this study for
subsequent studies.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |